no clear evidence for benefit with addition of rova-t to chemo for extensive sclc
Published 4 years ago • 69 plays • Length 0:58Download video MP4
Download video MP3
Similar videos
-
4:45
rova-t: first ‘targeted’ treatment for small cell lung cancer shows promise
-
7:14
safety and efficacy of single agent rovalpituzumab tesirine in small cell lung cancer (sclc)
-
3:30
immunotherapy treatments for non-small cell lung cancer (nsclc)
-
6:22
diagnosis and treatment of small cell lung cancer
-
2:03
chemoradiation and immunotherapy for patients with small cell lung cancer
-
1:30
immunotherapy in second-line treatment of non-small cell lung cancer
-
9:41
management of non-small cell lung cancer
-
1:12
updates in early stage non-small cell lung cancer
-
1:07
cell-free dna sequencing in the clinical setting
-
37:43
selective inhibition of oncogenic transcription and other approaches in the treatment of sclc
-
1:24
dr. pietanza on rova-t for small-cell lung cancer
-
3:38
what treatment options are available for small cell lung cancer?
-
4:58
rova-t shows promise in small cell lung cancer
-
0:49
should radiation be added to chemotherapy for induction treatment in lung cancer?
-
1:16
the importance of the phase iii javelin lung 100 trial in non-small-cell lung cancer
-
4:44
understanding non-small cell lung cancer
-
1:56
rovalpituzumab in small cell lung cancer (sclc)
-
5:53
targeted therapy in non-small cell lung cancer
-
41:11
optimizing treatment selection, sequencing, and tolerability in small cell lung cancer